Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL) and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.
